Prognos Review
VisitClinical data analytics for healthcare and life sciences
Prognos is a healthcare data analytics platform for life sciences and healthcare organizations.
AI Panel Score
6.9/10
6 AI reviews
Reviewed
Clinical data analytics for healthcare and life sciences
Prognos is a healthcare data analytics platform for life sciences and healthcare organizations.
AI Panel Score
6 AI reviews
Reviewed
Prognos Health provides a data and analytics platform that ingests clinical lab results, medical claims, and other structured healthcare data, then applies machine learning models to identify disease patterns, flag undiagnosed or misdiagnosed patients, and track treatment progression over time. Users, typically analysts and commercial teams at pharmaceutical and life sciences companies, access this data through dashboards and data feeds to inform decisions about patient targeting, market sizing, and clinical trial planning.
The platform's core differentiator is its diagnostic lab data network, which the company states draws from a large portion of adjudicated lab results across the U.S. adult population. On top of this data, Prognos builds condition-specific algorithms intended to detect disease earlier or more accurately than claims data alone, covering therapeutic areas such as oncology, cardiology, nephrology, and endocrinology. The platform also supports real-world evidence generation, patient journey mapping, and commercial analytics use cases like sales force targeting and market access strategy.
Prognos Health is aimed at pharmaceutical manufacturers, life sciences commercial and market access teams, and healthcare payers who need lab-based patient insights rather than general population health management tools. Pricing is not published and is handled through direct sales, consistent with enterprise healthcare data platforms. Comparable products in this space include Komodo Health, IQVIA, and Truveta.
The platform is delivered as a cloud-based service accessed via web dashboards and data delivery pipelines, with data integration built for enterprise clients in pharmaceutical and payer organizations rather than individual consumer use.
Over 900 proprietary and learning clinical algorithms that interpret raw lab data to identify and predict patient risk and enable earlier diagnosis.
Machine learning algorithms fill in missing provider information (such as NPI), identify test value outliers for validation, and tag lab tests across hundreds of millions of records.
Leverages deep genomic and biomarker data to identify and reach rare and ultra-rare patient populations for targeted research and commercialization.
Sophisticated healthcare provider segmentation tools that identify the right HCPs to educate at the right time, driving timely and sequential commercial messaging.
Combines lab and claims data to map diagnostic patterns, treatment initiation, continuation, and switches for a given patient population.
A machine-learning model applied to laboratory, prescription, and claims data that predicts future 12-month medical costs for prospective health insurance member groups.
Proprietary technology with 500,000+ rules that consolidates schemas, tokenizes and deduplicates patient records, and standardizes units, terminology, and medical coding (ICD, LOINC) across diverse lab sources.
A comprehensive marketplace and registry aggregating harmonized clinical lab and genomic data covering over 45 billion health records for 325 million de-identified patients across 50+ therapy areas.
Data and analytics are accessible through major cloud and data platforms including AWS Marketplace, Google Cloud Marketplace, Snowflake Marketplace, and Databricks Marketplace.
All data purchased through Prognos is available on the Datavant token, making it interoperable with other patient-level datasets such as claims, EHR, and prescription data.
A HIPAA-compliant, cloud-based platform serving as a single source for lab data results, providing broad connectivity to labs and delivering transformed data to payers via secure web services.
Simplifies access to high-fidelity, ready-to-use clinical and genomic real-world laboratory data that can complement existing data or serve as a comprehensive analytics solution.
Prognos (Prognos Health) is an enterprise healthcare data and analytics platform serving pharmaceutical manufacturers, payers, and life sciences companies; pricing is customized based on data scope, use case, and contract terms, requiring direct contact with the vendor.
325 million patients of lab data, no pricing page, and a sales team you'll need to call.
“Deep, differentiated lab data asset with 900+ clinical algorithms. But it's an enterprise sales motion, not a product you evaluate self-serve.”
325 million de-identified patients, 45 billion health records, 900+ proprietary algorithms. That's a real moat if the numbers hold up under diligence. Lab data is genuinely harder to aggregate than claims data, which is why Komodo Health and IQVIA lean more on claims and EHR breadth instead.
No pricing page, no free trial, no docs listed. Category norm for enterprise health data, but it means a 3-6 month procurement cycle before you see a single dashboard.
This is a commercial analytics buy, not an IT buy. If you're a pharma market access team choosing between Prognos, IQVIA, and Truveta, the lab-data depth is the differentiator worth the sales calls.
Lab-data specialization vs. claims-heavy rivals like Komodo Health and IQVIA is a defensible niche for early disease detection.
Datavant token interoperability and HIPAA-compliant DxCloud signal compliance maturity boards expect in health data vendors.
No self-serve trial or public pricing means value shows up only after a multi-month enterprise contracting process.
Purpose-built for pharma commercial and market access teams needing lab-based patient targeting, not a cost-saving swap.
Established registry claim of 325M patients and 45B records suggests years of data partnerships, not a startup pitch deck.
Pharma commercial teams and payers needing lab-based patient identification beyond claims data.
Skip if you need fast self-serve evaluation or a published price to justify the buy internally.
A commercial analytics engine wearing a clinical coat — useful for market planning, not bedside decisions.
“Prognos is a real-world-data asset for pharma commercial teams, not a diagnostic tool a clinician would ever touch. Its 900-plus algorithms and 325 million patient registry are impressive scale, but the value sits upstream of care, in targeting and trial design.”
As CMO I read this against one question: does it change what happens in the exam room? It doesn't. Prognos sits in commercial analytics — HCP targeting, patient journey mapping, rare disease cohort identification for trial recruitment. That's a legitimate and valuable lane, comparable to Komodo Health and IQVIA, but it's market science, not point-of-care decision support.
The data depth is genuine: 45 billion records, 325 million de-identified patients, 900+ algorithms tuned to lab signal rather than claims proxies alone. For a pharma market access team building a launch strategy or a payer modeling 12-month utilization, that's differentiated. For a health system CMO evaluating clinical workflow tools, it's the wrong shape entirely.
Three years in, this becomes a data-licensing dependency, not a clinical capability. Fine for life sciences; irrelevant for care delivery leadership.
Sits credibly alongside Komodo Health and IQVIA in RWD, differentiated by lab-first rather than claims-first data.
Built for pharma commercial and market access analysts, not for clinicians or clinical operations leadership.
Delivery via AWS, Google Cloud, Snowflake, and Databricks marketplaces fits an existing enterprise data stack cleanly.
Datavant token interoperability and multi-cloud marketplace access (AWS, Snowflake, Databricks) reduce lock-in risk over a 3-year horizon.
900+ proprietary algorithms and a 500,000-rule harmonization engine show real data science investment, not a thin dashboard layer.
Pharma commercial and market access teams needing lab-based patient targeting and real-world evidence.
Avoid if you need clinical decision support or point-of-care diagnostic tools for a health system.
Zero published pricing, 325 million patient records. Great data, opaque invoice.
“No pricing page, no tiers, no self-serve anything. Enterprise contract by definition — budget for a procurement cycle, not a signup.”
Contact Sales is the only tier. No published floor, no per-seat number, nothing to model against. Compare that to IQVIA or Komodo Health — same category, same opacity. Bait-free pricing pages don't exist here.
TCO math is unknowable without a quote. Enterprise healthcare data contracts run six or seven figures annually — data scope, therapy areas, integration depth all move the number. Add Datavant token licensing and cloud marketplace fees (AWS, Snowflake, Databricks) on top. Year 1 includes onboarding and data mapping costs nobody discloses upfront.
900+ clinical algorithms and 45 billion health records are real assets. But procurement gets a sales cycle, not a cart checkout. No free trial, no self-serve tier, no visible contract terms — term length, auto-renewal, cancellation, all negotiated blind. ROI story depends entirely on your use case: patient targeting and market sizing are measurable, but only after the deal closes and you can see the actual invoice.
Cloud marketplace access via AWS, Snowflake, Databricks may ease procurement for existing enterprise buyers of those platforms.
No terms published; category norm is multi-year lock-in with negotiated renewal.
Single 'Contact Sales' tier, no published price on the pricing page.
Use cases like HCP targeting and rare disease cohort ID are measurable once deployed, but no case studies with numbers provided.
Enterprise data contract with likely marketplace and integration fees stacked on an undisclosed base.
Pharma and payer teams with enterprise data budgets and a procurement team ready for a sales cycle.
You need a visible price to build a budget line before talking to sales.
Deep lab data, but this is a commercial analytics tool, not a bedside one.
“Prognos is built for pharma market access teams and payers mining lab data, not for clinicians at point of care. Strong data depth, but the workflow lives in dashboards and data pipelines, not the exam room.”
Let's be clear about who's actually logging in here: analysts and commercial teams at pharma companies, not physicians. The 900-algorithm library and 45 billion health records across 325 million de-identified patients are impressive scale, but nothing here touches an EHR at the point of care. That's fine if you're doing HCP targeting or patient journey mapping for a launch, less useful if you're trying to flag an undiagnosed diabetic in clinic today.
The Datavant token interoperability and marketplace access via Snowflake and Databricks suggest a mature data engineering team behind this, not a bolted-together vendor feed. No published pricing, enterprise-only sales cycle — standard for this category, same as Komodo Health or IQVIA, but it means procurement takes months, not a trial signup.
No docs, no API visibility in the evidence. For a data scientist trying to validate the 500,000+ harmonization rules against their own cohort logic, that's a real gap.
Dashboards and data feeds work fine once integrated, but there's no trial or sandbox to test fit before contracting.
No visible docs, API reference, or changelog in the evidence — capabilities table shows docs=N, API=N.
Enterprise sales cycle, no published pricing, and no free trial mean weeks of procurement friction before any hands-on use.
900+ algorithms and 50+ therapy areas suggest real depth for analysts who invest time learning the platform.
Fits commercial/market access workflows well via cloud marketplaces (AWS, Snowflake) but has no clinical point-of-care integration.
Pharma market access and commercial analytics teams needing lab-based patient targeting at scale.
Avoid if you need point-of-care clinical decision support rather than commercial data analytics.
A data platform built for analysts, but nobody let me touch it first.
“Prognos has serious numbers behind it, 325 million patients, 45 billion records, 900 algorithms. But there's zero public evidence of what using the thing day-to-day actually feels like.”
Here's my problem reviewing this one honestly: there's no product to poke at. No docs, no API reference, no pricing page, nothing scraped that shows me a dashboard or a login screen. Just a marketing site telling me about 900 clinical algorithms and 45 billion health records. That's a real number, and it's impressive, but numbers on a homepage aren't the same as a tool that respects your Tuesday afternoon.
Compare that to Komodo Health or IQVIA, competitors mentioned in the same breath, both of which at least have visible analyst workflows to reference. Prognos sells through direct contact only, so onboarding is a sales call, not a product tour. That's category norm for enterprise healthcare data, fine, but it means my usual day-3 read is impossible here.
The tradeoff: deep, differentiated lab data versus zero visibility into whether the actual dashboards are a joy or a chore.
No screenshots, docs, or UI evidence exist to judge whether the dashboards are refined.
900 algorithms and multiple marketplaces (AWS, Snowflake, Databricks) imply real depth, but also a lot to learn with no visible docs.
Platform is listed as web-only, no mobile mention anywhere in the evidence.
Sales-contact-only access with no free trial means onboarding is a procurement process, not a product experience.
500,000+ rule data harmonization engine and HIPAA-compliant DxCloud suggest engineering rigor even without visible uptime data.
Pharma commercial analytics teams that need lab-based patient targeting and already budget for enterprise data contracts.
You want to try before you buy or need anything beyond a web dashboard.
325 million patients in one paragraph, 215 million in another. Which is it?
“Real data asset, real enterprise clients probably. But the numbers don't hold still, and there's no pricing page to check anything against.”
About page says 325 million de-identified patients. Pricing plan says 215 million. That's not a rounding error, that's a hundred million patients of drift inside one site. Maybe genomic vs. lab-only cohorts. Maybe just stale copy. Either way, guard up.
The actual asset is credible: 900+ clinical algorithms, 45 billion records, Datavant token interoperability, marketplace listings on AWS, Snowflake, Databricks. That's infrastructure, not vaporware. Komodo Health and IQVIA play the same game with claims-heavy data; Truveta leans EHR. Prognos's lab-data angle is a real wedge, not a copycat pitch.
Exit portability is the real question nobody answers. No API docs, no changelog, no public integration spec. If you build commercial targeting workflows on prognosFACTOR, unwinding that in 18 months means renegotiating data rights, not just swapping a dashboard. Enterprise sales cycle, so at least the buyer isn't surprised by that part.
Lab-first data network is a distinct angle versus claims-heavy Komodo Health and IQVIA.
No public API or docs listed; migration depends on custom data delivery pipelines built per client.
Marketplace presence on AWS, Snowflake, and Databricks signals real distribution, though no funding or hiring data is public.
Two different patient-population numbers (325M vs 215M) on the same site undermines the headline stat.
Lab-data aggregation for pharma commercial teams is a proven, decade-old model, not a speculative pivot.
Pharma commercial and market access teams needing lab-based patient targeting at enterprise scale.
You need transparent pricing or self-serve access without a sales cycle.
Common questions answered by our AI research team
Prognos aggregates clinical lab data, claims data, and other healthcare datasets.
Prognos builds predictive models for conditions such as diabetes, kidney disease, and cardiovascular disorders.
Prognos uses both claims data and clinical lab data, not just labs.
Prognos states its diagnostic-focused data network covers lab results from a large share of the U.S. adult population.
